Background: Generation of α1,3-galactosyltransferase gene-knockout (GTKO) pigs that are also transgenic for human complement regulatory proteins (hCRP) may improve xenograft survival in the pig-to-primate model. In this study, complement activation was evaluated in primate recipients of a GTKO pig kidney expressing hCRP in a life supporting model. The impact of two different induction treatments on humoral responses and classical and alternative complement cascade was also evaluated. Methods: Ten bilaterally nephrectomized cynomolgus monkeys received a kidney from GTKO pigs transgenic for human CD39, CD55, CD59 and fucosyltransferase (FT). Animals in group 1 (n=6) received cyclophosphamide, cyclosporin A, mycophenolate sodium and steroids. Animals in Group 2 (n=4) received Rituximab instead of cyclophosphamide. IgM and IgG anti- donor porcine aortic endothelial cells (PAEC) were measured by flow cytometry preand post-transplantation. Classical and alternative complement pathway and properdin, C1q, C3, C4, complement fragments were also measured. Results: Median survival was 16 and 12 days in Group 1 and 2, respectively. Except for two animals, all primates were euthanized in the presence of kidney failure. In Group 1, anti-PAEC IgM and IgG increased in the first week and persisted throughout the post operative period. In Group 2, a limited amount of elicited anti pig antibodies was observed. A progressive activation of the classical and alternative pathway complement cascades was detected in both groups, with consumption of C1q, C4 and C3. In Group 2, a delay in classical pathway activation was observed. Additionally we detected a decrease in circulating properdin in agreement with alternative pathway involvement. Conclusion: In our model, rituximab therapy is useful in controlling anti-donor antibody production and delay the activation of the complement pathways. These studies implicate that a combination of inhibitory antibodies together with downmodulation of complement activation may be useful to control the rejection of xenotransplants using GTKO pig organs.

Study of complement activation in a life supporting pig to primate xenotransplantation model using GAL KO pigs

CAVICCHIOLI, LAURA;DE BENEDICTIS, GIULIA MARIA;CALABRESE, FIORELLA;Cozzi E.
2011

Abstract

Background: Generation of α1,3-galactosyltransferase gene-knockout (GTKO) pigs that are also transgenic for human complement regulatory proteins (hCRP) may improve xenograft survival in the pig-to-primate model. In this study, complement activation was evaluated in primate recipients of a GTKO pig kidney expressing hCRP in a life supporting model. The impact of two different induction treatments on humoral responses and classical and alternative complement cascade was also evaluated. Methods: Ten bilaterally nephrectomized cynomolgus monkeys received a kidney from GTKO pigs transgenic for human CD39, CD55, CD59 and fucosyltransferase (FT). Animals in group 1 (n=6) received cyclophosphamide, cyclosporin A, mycophenolate sodium and steroids. Animals in Group 2 (n=4) received Rituximab instead of cyclophosphamide. IgM and IgG anti- donor porcine aortic endothelial cells (PAEC) were measured by flow cytometry preand post-transplantation. Classical and alternative complement pathway and properdin, C1q, C3, C4, complement fragments were also measured. Results: Median survival was 16 and 12 days in Group 1 and 2, respectively. Except for two animals, all primates were euthanized in the presence of kidney failure. In Group 1, anti-PAEC IgM and IgG increased in the first week and persisted throughout the post operative period. In Group 2, a limited amount of elicited anti pig antibodies was observed. A progressive activation of the classical and alternative pathway complement cascades was detected in both groups, with consumption of C1q, C4 and C3. In Group 2, a delay in classical pathway activation was observed. Additionally we detected a decrease in circulating properdin in agreement with alternative pathway involvement. Conclusion: In our model, rituximab therapy is useful in controlling anti-donor antibody production and delay the activation of the complement pathways. These studies implicate that a combination of inhibitory antibodies together with downmodulation of complement activation may be useful to control the rejection of xenotransplants using GTKO pig organs.
2011
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11577/2475264
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact